CD8A and pancreatic neoplasm: As a proof-of-principle of this approach, immunization of transgenic humanized mice expressing HLA-A*02:01 with a long peptide containing the anchor-modified residue generated CD8+ T cells that recognize the original 9-mer peptide and a human HLA-A*02:01-positive pancreatic cancer cell line bearing the G12V mutation.